Aptevo Therapeutics Inc Cash Flow-to-Debt Ratio
Aptevo Therapeutics Inc cash flow-to-debt ratio. Aptevo Therapeutics Inc (APVO) has a Cash Flow-to-Debt Ratio of -0.64x as of June 2026, meaning its operating cash flow of $-5.45 Million could theoretically repay -1% of its total liabilities ($8.48 Million) in one year. Check Aptevo Therapeutics Inc (APVO) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Aptevo Therapeutics Inc (2014–2025)
Cash flow-to-debt ratio of Aptevo Therapeutics Inc from 2014 to 2025. Historical debt coverage capacity for Aptevo Therapeutics Inc across 12 annual periods. Check APVO total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Aptevo Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2014–2025)
Aptevo Therapeutics Inc cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Aptevo Therapeutics Inc. For the full cash flow conversion analysis, see Aptevo Therapeutics Inc cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.61x | $-25.59 Million | $9.81 Million | ▼ -18.8% |
| 2024 | -2.19x | $-23.79 Million | $10.84 Million | ▼ -136.2% |
| 2023 | -0.93x | $-11.73 Million | $12.62 Million | ▲ +28.2% |
| 2022 | -1.29x | $-21.02 Million | $16.24 Million | ▼ -230.7% |
| 2021 | -0.39x | $-21.68 Million | $55.38 Million | ▲ +50.7% |
| 2020 | -0.79x | $-29.32 Million | $36.95 Million | ▲ +22.2% |
| 2019 | -1.02x | $-42.38 Million | $41.57 Million | ▲ +26.5% |
| 2018 | -1.39x | $-51.42 Million | $37.09 Million | ▼ -16.6% |
| 2017 | -1.19x | $-41.57 Million | $34.97 Million | ▼ -33.2% |
| 2016 | -0.89x | $-36.86 Million | $41.29 Million | ▲ +56.4% |
| 2015 | -2.05x | $-48.76 Million | $23.84 Million | ▼ -10.4% |
| 2014 | -1.85x | $-47.01 Million | $25.36 Million | — |